China National Medicines's quarterly market cap
increased
from Sep. 2025 (¥21,579 Mil) to Dec. 2025 (¥21,692 Mil) and
increased
from Dec. 2025 (¥21,692 Mil) to Mar. 2026 (¥22,107 Mil).
China National Medicines's annual market cap
increased
from Dec. 2023 (¥21,594 Mil) to Dec. 2024 (¥25,819 Mil) but then
declined
from Dec. 2024 (¥25,819 Mil) to Dec. 2025 (¥21,692 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. China National Medicines's Enterprise Value for Today is ¥14,803 Mil.
China National Medicines (SHSE:600511) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
China National Medicines Market Cap Related Terms
China National Medicines Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:600511 vs MCK, CAH, COR: Market Cap Comparison
For the Medical Distribution subindustry, China National Medicines's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China National Medicines Market Cap vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, China National Medicines's Market Cap distribution charts can be found below:
* The bar in red indicates where China National Medicines's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
China National Medicines's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China National Medicines (SHSE:600511) has a Market Cap of ¥20,326 Mil as of Jul. 04, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on China National Medicines and its competitors. According to the industry distribution chart, China National Medicines ranks #13 out of 120 companies in the Medical Distribution industry, placing it in the top 10.8%.
Is China National Medicines' Market Cap too high?
China National Medicines' current Market Cap is ¥20,326 Mil. Based on the distribution chart, China National Medicines ranks #13 out of 120 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, China National Medicines has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China National Medicines' Market Cap compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, China National Medicines ranks #13 out of 120 companies for Market Cap. This places China National Medicines in the top 11% of its industry — outperforming the majority of peers. The industry median Market Cap is 146.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Distribution company?
The median Market Cap among Medical Distribution companies is 146.50, based on 120 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on China National Medicines and its competitors. For the Medical Distribution industry, the median Market Cap is 146.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China National Medicines's current Market Cap is ¥20,326 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China National Medicines stock overvalued right now?
Based on GuruFocus' analysis, China National Medicines (SHSE:600511) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥32.74, compared to a current price of ¥26.94 — trading 17.7% below its estimated fair value. The current Market Cap is ¥20,326 Mil. China National Medicines' overall GF Score™ is 86/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For China National Medicines (SHSE:600511), the current Market Cap is ¥20,326 Mil as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China National Medicines (SHSE:600511) Overvalued in 2026?
Based on GuruFocus' analysis, China National Medicines stock appears to be undervalued.
The current stock price of ¥26.94 is trading 17.7% below its estimated GF Value™ of ¥32.74.
GuruFocus considers China National Medicines to be Modestly Undervalued.
Key valuation signals for SHSE:600511:
Market Cap: ¥20,326 Mil
GF Value™: ¥32.74 vs. price of ¥26.94 (17.7% below fair value)
No single metric tells the full story. See the SHSE:600511 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China National Medicines Corp Ltd focuses on producing special drugs and high-end prescription drugs. Its main goal is to provide customers with professional medical services. The company conducts its operations through two primary segments. The Commercial segment is mainly engaged in the sale of pharmaceuticals. The Others segment focuses on pharmaceutical manufacturing and logistics operations.
86GF Score
Get the complete analysis for SHSE:600511
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600511 has been successfully added to your 
